Long-term efficacy and safety of ruxolitinib versus best available therapy in polycythaemia vera (RESPONSE): 5-year follow up of a phase 3 study.
暂无分享,去创建一个
M. Griesshammer | S. Verstovsek | M. Hino | R. Mesa | A. Vannucchi | V. Rosti | F. Passamonti | C. Harrison | K. Kirito | Carole B. Miller | F. Pane | T. Masszi | E. Rumi | S. Durrant | C. Besses | T. Dong | P. Zachée | J. Kiladjian | I. Blau | B. Moiraghi | M. Wroclawska | Nathalie Francillard